Bio-Rad is a global leader in life science research and clinical diagnostics. Its products power everything from basic research discovery to healthcare improvements, including applications in liquid biopsy. For assessing CTC phenotype and discerning overall tumor prognosis, Celselect Technology is combined with the Genesis system to process liquid biopsies for cell enrichment and enumeration. Isolated cells can be retrieved for various analysis methods, including immunohistochemical staining. Assessing ctDNA is simplified with Droplet Digital PCR (ddPCR), which offers unrivaled detection and absolute quantification of nucleic acid. ddPCR provides industry-leading sensitivity, specificity, and unmatched precision when generating liquid biopsy data. Paired with Bio-Rad's Precision Monitoring portfolio, it provides a complete clinical research solution. Bio-Rad’s Celselect Technology along with its Genesis and ddPCR platforms offer a synergistic, unparalleled degree of insight into unique biomolecular signatures of CTCs.